These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27215560)

  • 1. 23-Valent Pneumococcal Polysaccharide Vaccine Uptake in the United States Air Force HIV Program.
    Ocampo TF; Le T; Matthews PE; Okulicz JF
    J Int Assoc Provid AIDS Care; 2016 Jul; 15(4):286-90. PubMed ID: 27215560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
    Ho YL; Brandão AP; de Cunto Brandileone MC; Lopes MH
    Vaccine; 2013 Aug; 31(37):4047-53. PubMed ID: 23684823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
    Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
    Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
    Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
    Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Zou X; He J; Zheng J; Liang M; Gao J; Huang J; Jiang Y; Jiang Y; Chen X
    Vaccine; 2022 Jan; 40(1):37-42. PubMed ID: 34857419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    Farmaki PF; Chini MC; Mangafas NM; Tzanoudaki MT; Piperi CP; Lazanas MZ; Spoulou VS
    J Infect Dis; 2018 Jun; 218(1):26-34. PubMed ID: 29722823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptococcus pneumoniae colonization among patients with human immunodeficiency virus-1 who had received 23-valent polysaccharide pneumococcal vaccine.
    Lo YC; Lauderdale TL; Chang SY; Hsiao CF; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2009 Jun; 42(3):234-42. PubMed ID: 19812857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal vaccination patterns among persons aged 65 years or older in the United States: A retrospective database analysis.
    Yang X; Zhang D; Ou W
    Vaccine; 2018 Nov; 36(49):7574-7579. PubMed ID: 30391053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan.
    Naito T; Yokokawa H; Watanabe A
    J Infect Chemother; 2018 Jun; 24(6):496-498. PubMed ID: 29398479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
    Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
    Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Declining invasive pneumococcal disease in the U.S. elderly.
    McBean AM; Park YT; Caldwell D; Yu X
    Vaccine; 2005 Dec; 23(48-49):5641-5. PubMed ID: 16111788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal Vaccination Strategies Among HIV-infected Adult Patients: A Review of the Literature.
    Garmpi A; Damaskos C; Garmpis N; Patsouras A; Savvanis S; Gravvanis N; Diamantis E
    In Vivo; 2019; 33(5):1425-1430. PubMed ID: 31471388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
    Andrews NJ; Waight PA; George RC; Slack MP; Miller E
    Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A virtual clinic improves pneumococcal vaccination coverage among patients living with HIV at a Veterans Affairs Medical Center.
    Burns CM; Banks RE; Wilson BM; Carter RR; Jump RLP; Perez F
    AIDS Care; 2018 Feb; 30(2):146-149. PubMed ID: 29052434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of 23-valent pneumococcal polysaccharide vaccine on adult pneumococcal disease].
    Li MC; Shao ZJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):1003-1009. PubMed ID: 32907293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.